Stadius Biopharma LLC is a biopharmaceutical company based in New Orleans, LA, dedicated to developing innovative antibody therapeutics and a stem cell antibody delivery system for the prevention and treatment of resistant and life-threatening bacterial, fungal, and viral infections in immunocompromised patients.
Led by a team of experienced scientists and industry professionals, Stadius Biopharma focuses on addressing the challenges posed by opportunistic infections and the development of drug resistance, with a particular emphasis on invasive fungal infections. Their research is centered around the discovery and development of fully human monoclonal and bispecific antibodies, as well as the delivery of these proteins using their patented non-viral gene modified adipose derived mesenchymal stem cell platform.
Generated from the website